



**HAL**  
open science

## Association Between Early Amino Acid Intake and Full-Scale IQ at Age 5 Years Among Infants Born at Less Than 30 Weeks' Gestation

Jean-Christophe Rozé, Baptiste Morel, Alexandre Lapillonne, Stéphane Marret, Isabelle Guellec, Dominique Darmaun, Nathalie Bednarek, Thomas Moyon, Laetitia Marchand-Martin, Valérie Benhammou, et al.

► **To cite this version:**

Jean-Christophe Rozé, Baptiste Morel, Alexandre Lapillonne, Stéphane Marret, Isabelle Guellec, et al.. Association Between Early Amino Acid Intake and Full-Scale IQ at Age 5 Years Among Infants Born at Less Than 30 Weeks' Gestation. *JAMA Network Open*, 2021, 4 (11), pp.e2135452. 10.1001/jamanetworkopen.2021.35452 . hal-03466832

**HAL Id: hal-03466832**

<https://hal.sorbonne-universite.fr/hal-03466832v1>

Submitted on 6 Dec 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



# Association Between Early Amino Acid Intake and Full-Scale IQ at Age 5 Years Among Infants Born at Less Than 30 Weeks' Gestation

Jean-Christophe Rozé, MD, PhD; Baptiste Morel, MD, PhD; Alexandre Lapillonne, MD, PhD; Stéphane Marret, MD, PhD; Isabelle Guellec, MD, PhD; Dominique Darmaun, MD, PhD; Nathalie Bednarek, MD, PhD; Thomas Moyon, MSc; Laetitia Marchand-Martin, MSc; Valérie Benhammou, MSc; Véronique Pierrat, MD, PhD; Cyril Flamant, MD, PhD; Géraldine Gascoin, MD, PhD; Delphine Mitanchez, MD, PhD; Gilles Cambonie, MD, PhD; Laurent Storme, MD, PhD; Bathélemie Tosello, MD, PhD; Valérie Biran, MD, PhD; Olivier Claris, MD, PhD; Jean-Charles Picaud, MD, PhD; Géraldine Favrais, MD, PhD; Alain Beuchée, MD, PhD; Gauthier Loron, MD; Catherine Gire, MD; Xavier Durrmeyer, MD, PhD; Pierre Gressens, MD, PhD; Elie Saliba, MD, PhD; Pierre-Yves Ancel, MD, PhD; for the Nutrition EPIPAGE-2 Study Group and the EPIRMEX Study Group

## Abstract

**IMPORTANCE** An international expert committee recently revised its recommendations on amino acid intake for very preterm infants, suggesting that more than 3.50 g/kg/d should be administered only to preterm infants in clinical trials. However, the optimal amino acid intake during the first week after birth in these infants is unknown.

**OBJECTIVE** To evaluate the association between early amino acid intake and cognitive outcomes at age 5 years.

**DESIGN, SETTING, AND PARTICIPANTS** Using the EPIPAGE-2 (Epidemiologic Study on Small-for-Gestational-Age Children—Follow-up at Five and a Half Years) cohort, a nationwide prospective population-based cohort study conducted at 63 neonatal intensive care units in France, a propensity score-matched analysis was performed comparing infants born at less than 30 weeks' gestation who had high amino acid intake (3.51-4.50 g/kg/d) at 7 days after birth with infants who did not. Participants were recruited between April 1 and December 31, 2011, and followed up from September 1, 2016, to December 31, 2017. Full-scale IQ (FSIQ) was assessed at age 5 years. A confirmatory analysis used neonatal intensive care unit preference for high early amino acid intake as an instrumental variable to account for unmeasured confounding. Statistical analysis was performed from January 15 to May 15, 2021.

**EXPOSURES** Amino acid intake at 7 days after birth.

**MAIN OUTCOMES AND MEASURES** The primary outcome was an FSIQ score greater than -1 SD (ie,  $\geq 93$  points) at age 5 years. A complementary analysis was performed to explore the association between amino acid intake at day 7 as a continuous variable and FSIQ score at age 5 years. Data from cerebral magnetic resonance imaging at term were available for a subgroup of preterm infants who participated in the EPIRMEX (Cerebral Abnormalities Detected by MRI, Realized at the Age of Term and the Emergence of Executive Functions) ancillary study.

**RESULTS** Among 1789 preterm infants (929 boys [51.9%]; mean [SD] gestational age, 27.17 [1.50] weeks) with data available to determine exposure to amino acid intake of 3.51 to 4.50 g/kg/d at 7 days after birth, 938 infants were exposed, and 851 infants were not; 717 infants from each group could be paired. The primary outcome was known in 396 of 646 exposed infants and 379 of 644 nonexposed infants who were alive at age 5 years and was observed more frequently among exposed vs nonexposed infants (243 infants [61.4%] vs 206 infants [54.4%], respectively; odds ratio [OR], 1.33 [95% CI, 1.00-1.71]; absolute risk increase in events [ie, the likelihood of having an FSIQ

(continued)

## Key Points

**Question** Is early amino acid intake among very preterm infants associated with cognitive performance at age 5 years?

**Findings** In this cohort study of 1789 infants born at less than 30 weeks' gestation, exposure vs nonexposure to amino acid intake between 3.51 and 4.50 g/kg/d at 7 days after birth was significantly and independently associated with a higher likelihood (61% vs 54%, respectively) of surviving with a full-scale IQ score greater than -1 SD at age 5 years.

**Meaning** The results of this study suggest that high early amino acid intake among very preterm infants is safe and significantly associated with improved cognitive outcomes at age 5 years.

## + Supplemental content

Author affiliations and article information are listed at the end of this article.

**Open Access.** This is an open access article distributed under the terms of the CC-BY License.

Abstract (continued)

score  $>-1$  SD at age 5 years] per 100 infants, 7.01 [95% CI, 0.06-13.87];  $P = .048$ ). In the matched cohort, correlation was found between amino acid intake per 1.00 g/kg/d at day 7 and FSIQ score at age 5 years ( $n = 775$ ;  $\beta = 2.43$  per 1-point increase in FSIQ; 95% CI, 0.27-4.59;  $P = .03$ ), white matter area ( $n = 134$ ;  $\beta = 144$  per  $\text{mm}^2$ ; 95% CI, 3-285 per  $\text{mm}^2$ ;  $P = .045$ ), anisotropy of the corpus callosum ( $n = 50$ ;  $\beta = 0.018$ ; 95% CI, 0.016-0.021;  $P < .001$ ), left superior longitudinal fasciculus ( $n = 42$ ;  $\beta = 0.018$ ; 95% CI, 0.010-0.025;  $P < .001$ ), and right superior longitudinal fasciculus ( $n = 42$ ;  $\beta = 0.014$  [95% CI, 0.005-0.024;  $P = .003$ ) based on magnetic resonance imaging at term. Confirmatory and sensitivity analyses confirmed these results. For example, the adjusted OR for the association between the exposure and the primary outcome was 1.30 (95% CI, 1.16-1.46) using the instrumental variable approach among 978 participants in the overall cohort, and the adjusted OR was 1.35 (95% CI, 1.05-1.75) using multiple imputations among 1290 participants in the matched cohort.

**CONCLUSIONS AND RELEVANCE** In this cohort study, high amino acid intake at 7 days after birth was associated with an increased likelihood of an FSIQ score greater than  $-1$  SD at age 5 years. Well-designed randomized studies with long-term follow-up are needed to confirm the benefit of this nutritional approach.

JAMA Network Open. 2021;4(11):e2135452. doi:10.1001/jamanetworkopen.2021.35452

## Introduction

Very preterm infants (ie, infants born at  $<32$  weeks' gestation) are at high risk of developing cognitive difficulties.<sup>1</sup> Although low early nutritional intake seems to play a role in the occurrence of these difficulties,<sup>2</sup> the optimal early intake of amino acids is not known. Between 2000 and 2005, international expert committees<sup>2-5</sup> recommended providing more than 3.50 g/kg/d of protein at the end of the first week after birth to match the net maternal-fetal amino acid transfer during the third trimester of gestation based on net leucine uptake, obligate protein loss, efficiency of protein retention, and required protein accretion.<sup>6</sup> In 2018, a European expert committee revised these recommendations and suggested that amino acid intake higher than 3.50 g/kg/d should be administered only as part of clinical trials.<sup>7</sup>

The change in recommendation was likely motivated by the results of randomized clinical trials published between these 2 periods. Observational studies, with their limitations, have emphasized the association between amino acid intake during the first week after birth and short-term neurodevelopmental outcomes<sup>8</sup> or the association between amino acid intake and brain growth,<sup>9</sup> accelerated white matter maturation at term,<sup>10</sup> and more robust functional connectivity in school-aged children who were born preterm<sup>11</sup>; however, no firm conclusion can be drawn from the results of randomized clinical trials.<sup>12</sup> Only a few randomized studies have assessed the impact of early amino acid intake for neurodevelopment,<sup>13-17</sup> and the benefit of early amino acid intake of 4.00 g/kg/d remains controversial.<sup>7</sup> Concern has been expressed because high early amino acid intake was associated with a smaller head circumference among infants of both sexes in 1 study,<sup>16</sup> and a lower mental developmental index was observed among a subgroup of girls who survived without disability in another study.<sup>17</sup>

Although randomized studies have not yielded clear conclusions because of the difficulties in conducting large randomized clinical trials with long-term follow-up, large observational studies can help to assess a complex therapeutic strategy.<sup>18</sup> The EPIPAGE-2 (Epidemiologic Study on Small-for-Gestational-Age Children—Follow-up at Five and a Half Years),<sup>1</sup> a nationwide population-based prospective cohort study, provided a rare and distinct opportunity to explore the association between early amino acid intake and outcomes at age 5 years among unselected preterm infants born before 30 weeks' gestational age and hospitalized in unselected neonatal intensive care units

(NICUs). Exploring this issue was possible because of the wide range of variation in practice associated with low adherence to the recommendations available in 2011,<sup>19</sup> the period during which the EPIPAGE-2 study was conducted.

---

## Methods

### Study Population

Recruitment took place at birth in all NICUs in France from April 1 to December 31, 2011. Eligible children were those born at 24 to 29 weeks' gestation, admitted to the NICU, alive at 7 days after birth, and with information available regarding amino acid intake at 7 days after birth. Children were followed up from September 1, 2016, to December 31, 2017. The study was approved by the National Data Protection Authority, the Consultative Committee on the Treatment of Information on Personal Health Data for Research Purposes, and the Committee for the Protection of People Participating in Biomedical Research.<sup>1</sup> Recruitment and data collection occurred only after families had received information and provided oral informed consent to participate in the study. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies.

### Amino Acid Intake at 7 Days After Birth

Preterm infants were separated into 2 groups, exposed and nonexposed, based on whether they had been prescribed a high amino acid intake (defined as 3.51-4.50 g/kg/d at 7 days after birth), as recommended by the American National Institute of Child Health and Human Development,<sup>3</sup> the European Society of Paediatric Gastroenterology, Hepatology and Nutrition,<sup>4</sup> and the European Society for Clinical Nutrition and Metabolism<sup>5</sup> in 2011. In the EPIPAGE-2 study, information about nutritional intake was recorded at days 3, 7, and 28 and at hospital discharge. All data were prospectively collected during NICU hospitalization.

### Outcomes

The primary outcome was binary and defined as a full-scale IQ (FSIQ) score greater than -1 SD (ie,  $\geq 93$  points) at age 5 years compared with a contemporaneous group of term-born children enrolled in the EPIPAGE-2 follow-up study.<sup>1</sup> Full-scale IQ was assessed using the French version of the Wechsler Preschool and Primary Scale of Intelligence, 4th edition.<sup>20</sup> The secondary outcome was FSIQ score at age 5 years considered as a continuous variable. A secondary intermediate outcome was the surface area of white and gray matter and fractional anisotropy (a scalar value between 0 and 1 that describes the extent of anisotropy in the diffusion process, with 0 indicating that diffusion is isotropic and unrestricted in all directions and 1 indicating that diffusion is occurring only along 1 axis and is fully restricted in all other directions) measured by magnetic resonance imaging (MRI) performed at term among the subgroup of preterm infants enrolled in the EPIRMEX (Cerebral Abnormalities Detected by MRI, Realized at the Age of Term and the Emergence of Executive Functions) study,<sup>21</sup> an ancillary study of the EPIPAGE-2 cohort (eMethods 1 in Supplement 1).

### Statistical Analysis

The main analysis included 1789 children with complete data. We analyzed the association between the exposure and the primary outcome using a propensity score approach<sup>22</sup> to control for observed confounding factors that might have consequences for both group assignment (exposed vs nonexposed) and outcome. The propensity score of each infant was defined as the probability of having an amino acid intake greater than 3.50 g/kg/d based on the infant's individual observed covariates. The score was estimated using a logistic regression model, with amino acid intake greater than 3.50 g/kg/d as the dependent variable with regard to baseline maternal, infant, and NICU characteristics. Birth weight z scores were based on Olsen curves.<sup>23</sup> The proportion of participants

with missing data ranged from 0% to 8.5%, exceeding 4.0% only for data on Apgar score at 5 minutes and maternal educational level. Missing data were treated as a separate category.

The primary analysis was based on propensity score matching. We used a 1:1 matching algorithm without replacement to match exposed and nonexposed newborns based on propensity score within a caliper of 0.2 SD of the logit of the propensity score.<sup>24</sup> Imbalance after matching was checked. Odds ratios (ORs) were then calculated to quantify the association between high amino acid intake at day 7 and the primary outcome using logistic regression analysis fit by generalized estimating equations to account for paired data.<sup>25</sup> Confirmatory analyses were performed for the overall cohort after adjusting for gestational age, sex, birth weight z score, and maternal educational level, using the inverse probability weights method and accounting for NICU clustering.<sup>26</sup>

We used an instrumental variable approach as a confirmatory analysis of the principal analysis because propensity score cannot remove hidden biases from unmeasured confounders.<sup>27</sup> We used NICU preference for high amino acid intake at day 7 as a preference-based measure, with estimated random NICU factors categorized into quartiles (eMethods 2 in Supplement 1).<sup>28,29</sup> Instrumental variable analysis was performed using the 2-stage residual inclusion approach,<sup>30</sup> with additional adjustment for gestational age, sex, birth weight z score, and maternal educational level.

Complementary analyses were performed using FSIQ score as a continuous variable. First, we measured the Spearman correlation between FSIQ score and amino acid intake as a continuous variable in the matched cohort. In the overall cohort, we used general linear equations and adjustment for gestational age, sex, and birth weight z score, weighted by the inverse of the propensity score and accounting for NICU clustering. We completed these analyses by evaluating the Spearman correlation between amino acid intake as a continuous variable and white matter area, gray matter area, and mean fractional anisotropy of cerebral white matter tracts. We compared these outcomes among 4 subgroups of amino acid intake (<3.00, 3.01-3.50, 3.51-4.00, and 4.01-4.50 g/kg/d).

Sensitivity analyses were performed using multiple imputation of missing FSIQ scores. Forty multiple imputation data sets built with predictive mean matching using the mice package in R software, version 4.0.2 (R Foundation for Statistical Computing), were analyzed using variables that were included in the propensity score, morbidities observed during neonatal hospitalization, results from the Ages and Stages questionnaire<sup>31</sup> (which was completed by parents when children were at the corrected age of 2 years), and deficiencies observed at age 5 years.<sup>1</sup> Each imputed data set was then analyzed, and the resulting estimates were pooled according to the Rubin rules.<sup>32</sup> We also analyzed the Spearman correlation between amino acid intake at 7 days after birth and FSIQ score at age 5 years among different subpopulations of participants in the matched cohort with complete data, corresponding to potential confounding factors (presence of bronchopulmonary dysplasia, presence of late-onset sepsis, exposure to maternal breast milk, and presence of severe illness in the first week of life [defined by acute kidney failure and/or the receipt of catecholamine treatment during the first week]). Using the Fine generalized estimating equation, we performed a negative control analysis using survival without morbidity at 36 weeks as a negative control outcome to detect uncontrolled confounding via the propensity score approach.<sup>33</sup> All tests were 2-sided, and  $P < .05$  was considered statistically significant. All analyses were performed using R software, version 4.0.2 (R Foundation for Statistical Computing). Data were analyzed from January 15 to May 15, 2021.

---

## Results

### Study Population

Among 2136 preterm infants admitted to NICUs during the study period, 170 infants died within the first 7 days, leaving 1966 infants alive at day 7. Of those, information about amino acid intake at day 7 was available for 1789 infants (mean [SD] gestational age, 27.17 [1.50] weeks; 929 boys [51.9%]); 860 girls [48.1%]; mean [SD] birth weight z score, -0.09 [1.00]); 938 of those infants (52.4%) had amino acid intake greater than 3.50 g/kg/d (exposed group), and 851 infants (47.6%) did not (nonexposed

group) (Figure 1). Infants were hospitalized in 63 NICUs across France, and exposure to amino acid intake of 3.51 to 4.50 g/kg/d varied from 0% to 100% (eFigure 1 in Supplement 1). In the overall cohort, infants in the exposed vs nonexposed group were more likely to be female (478 infants [51.0%] vs 382 infants [44.9%], respectively), have mothers with an educational level higher than high school (429 infants [45.7%] vs 316 infants [37.1%]), and have antenatal corticosteroid receipt (615 infants [65.6%] vs 515 infants [60.5%]) but less likely to have acute kidney failure (59 infants [6.3%] vs 107 infants [12.6%]) and assisted ventilation at day 7 (366 infants [39.0%] vs 409 infants [48.1%]). Additional characteristics of exposed vs nonexposed infants in the overall cohort are shown in Table 1.


**Propensity Score–Matched Analysis**

Propensity scores were calculated for 1789 infants in the overall cohort and ranged from 0.095 to 0.922. Distributions of propensity scores are summarized in eFigure 2 in Supplement 1. The area under the receiver operating characteristic curve for the propensity score model was 0.67 (95% CI, 0.64-0.69). A total of 1434 of 1789 infants could be matched, with 717 infants in each group (exposed and nonexposed). The matched groups were well balanced in all recorded baseline variables (eg, exposed infants: 341 girls [46.7%] with a mean [SD] gestational age of 27.17 [1.47] weeks; nonexposed infants: 331 girls [46.2%] with a mean [SD] gestational age of 27.21 [1.55] weeks) (Table 1).

Characteristics of nutritional intake at 3, 7, and 28 days after birth and outcomes at 36 weeks' postmenstrual age are shown in Table 2. Nutritional intakes at day 3 and day 7 were significantly correlated (Spearman  $r = 0.41$ ;  $P < .001$ ) (eFigure 3 in Supplement 1).

In the matched cohort, survival rates at age 5 years were similar between the exposed (646 infants [90.1%]) and nonexposed (644 infants [89.8%]) groups. The primary outcome was known for 396 of 646 exposed infants (61.3%) and 379 of 644 nonexposed infants (58.9%) who were alive at age 5 years (Table 2). The characteristics of preterm infants alive at age 5 years with vs without FSIQ scores were not significantly different (eg, 408 of 775 boys [52.6%] vs 275 of 515 boys [53.4%], respectively; mean [SD] birth weight z score,  $-0.09$  [0.99] vs  $-0.02$  [0.97]; mean [SD] gestational

Figure 1. Flowchart of Study Population



FSIQ indicates full-scale IQ; MRI, magnetic resonance imaging.

Table 1. Baseline Participant Characteristics

| Characteristic   | Overall cohort (N = 1789) |              |                         | Matched cohort (n = 1434) |              |                         |
|--|---------------------------|--------------|-------------------------|---------------------------|--------------|-------------------------|
|  | No. (%)                   |              | Standardized difference | No. (%)                   |              | Standardized difference |
|  | Nonexposed                | Exposed      |                         | Nonexposed                | Exposed      |                         |
| Total participants, No.                                  | 851                       | 938          | NA                      | 717                       | 717          | NA                      |
| Maternal educational level                               |                           |              |                         |                           |              |                         |
| <High school   | 241 (28.3)                | 231 (24.6)   | 8.37                    | 194 (27.1)                | 193 (26.9)   | 0.32                    |
| High school  | 157 (18.4)                | 175 (18.7)   | 0.54                    | 137 (19.1)                | 134 (18.7)   | 1.07                    |
| >High school   | 316 (37.1)                | 429 (45.7)   | 17.55                   | 291 (40.6)                | 295 (41.1)   | 1.12                    |
| Missing data   | 137 (16.1)                | 103 (11.0)   | 15.01                   | 95 (13.2)                 | 95 (13.2)    | 0                       |
| Gestational age at birth, mean (SD), wk                  | 27.16 (1.55)              | 27.18 (1.46) | 1.33                    | 27.21 (1.55)              | 27.17 (1.47) | 2.65                    |
| Birth weight z score, mean (SD) <sup>a</sup>             | -0.10 (0.99)              | -0.09 (1.01) | 1.00                    | -0.07 (0.97)              | -0.07 (1.01) | 0                       |
| Sex  |                           |              |                         |                           |              |                         |
| Male   | 469 (55.1)                | 460 (49.0)   | 12.11                   | 386 (53.8)                | 376 (52.4)   | 2.81                    |
| Female   | 382 (44.9)                | 478 (51.0)   |                         | 331 (46.2)                | 341 (47.6)   |                         |
| Reason for preterm delivery                              |                           |              |                         |                           |              |                         |
| Twin or triplet  | 288 (33.8)                | 287 (30.6)   | 6.94                    | 242 (33.8)                | 225 (31.4)   | 5.06                    |
| Singleton with preterm labor                             | 239 (28.1)                | 251 (26.8)   | 2.96                    | 195 (27.2)                | 207 (28.9)   | 3.72                    |
| Singleton with preterm rupture of membranes              | 127 (14.9)                | 164 (17.5)   | 6.95                    | 113 (15.8)                | 114 (15.9)   | 0.38                    |
| Singleton with vascular disorders and FGR                | 66 (7.8)                  | 71 (7.6)     | 0.71                    | 55 (7.7)                  | 56 (7.8)     | 0.52                    |
| Singleton with vascular disorders and no FGR             | 76 (8.9)                  | 82 (8.7)     | 0.67                    | 63 (8.8)                  | 63 (8.8)     | 0                       |
| Singleton with placental abruption                       | 11 (1.3)                  | 13 (1.4)     | 0.87                    | 10 (1.4)                  | 10 (1.4)     | 0                       |
| Singleton with isolated FGR                              | 24 (2.8)                  | 34 (3.6)     | 4.53                    | 22 (3.1)                  | 23 (3.2)     | 0.80                    |
| Missing data   | 20 (2.4)                  | 36 (3.8)     | 8.61                    | 17 (2.4)                  | 19 (2.6)     | 1.79                    |
| Antenatal corticosteroid receipt                         |                           |              |                         |                           |              |                         |
| No   | 143 (16.8)                | 160 (17.1)   | 0.69                    | 114 (15.9)                | 122 (17.0)   | 3.02                    |
| Yes  | 515 (60.5)                | 615 (65.6)   | 10.48                   | 457 (63.7)                | 451 (62.9)   | 1.72                    |
| Incomplete cure  | 163 (19.2)                | 130 (13.9)   | 14.27                   | 116 (16.2)                | 115 (16.0)   | 0.38                    |
| Missing data   | 30 (3.5)                  | 33 (3.5)     | 0.05                    | 30 (4.2)                  | 29 (4.0)     | 0.71                    |
| Cesarean delivery  |                           |              |                         |                           |              |                         |
| Yes  | 530 (62.3)                | 563 (60.0)   | 4.64                    | 450 (62.8)                | 435 (60.7)   | 4.30                    |
| Missing data   | 13 (1.5)                  | 8 (0.9)      | 6.27                    | 5 (0.7)                   | 6 (0.8)      | 1.60                    |
| Apgar score ≥7 at 5 min after birth                      |                           |              |                         |                           |              |                         |
| Yes  | 586 (68.9)                | 684 (72.9)   | 8.95                    | 505 (70.4)                | 507 (70.7)   | 0.61                    |
| Missing data   | 77 (9.0)                  | 54 (5.8)     | 12.59                   | 52 (7.3)                  | 50 (7.0)     | 1.09                    |
| Regular intestinal transit during first week after birth |                           |              |                         |                           |              |                         |
| Yes  | 430 (50.5)                | 499 (53.2)   | 5.35                    | 359 (50.1)                | 379 (52.9)   | 5.58                    |
| Missing data   | 34 (4.0)                  | 43 (4.6)     | 2.86                    | 31 (4.3)                  | 31 (4.3)     | 0                       |
| Acute kidney failure                                     |                           |              |                         |                           |              |                         |
| Yes  | 107 (12.6)                | 59 (6.3)     | 17.31                   | 59 (8.2)                  | 56 (7.8)     | 1.55                    |
| Missing data   | 23 (2.7)                  | 31 (3.3)     | 3.52                    | 20 (2.8)                  | 19 (2.6)     | 2.54                    |
| Surfactant receipt                                       |                           |              |                         |                           |              |                         |
| No   | 143 (16.8)                | 149 (15.9)   | 2.49                    | 127 (17.7)                | 117 (16.3)   | 3.70                    |
| 1 Dose   | 493 (57.9)                | 578 (61.6)   | 7.53                    | 421 (58.7)                | 430 (60.0)   | 2.55                    |
| >2 Doses   | 211 (24.8)                | 209 (22.3)   | 5.9                     | 167 (23.3)                | 168 (23.4)   | 0.33                    |
| Missing data   | 4 (0.5)                   | 2 (0.2)      | 4.47                    | 2 (0.3)                   | 2 (0.3)      | 0                       |
| Assisted ventilation at day 7                            |                           |              |                         |                           |              |                         |
| Yes  | 409 (48.1)                | 366 (39.0)   | 18.31                   | 314 (43.79)               | 282 (39.3)   | 9.06                    |
| Missing data   | 3 (0.4)                   | 11 (1.2)     | 9.45                    | 2 (0.3)                   | 4 (0.6)      | 4.33                    |

(continued)

Table 1. Baseline Participant Characteristics (continued)

| Characteristic   | Overall cohort (N = 1789) |            |                         | Matched cohort (n = 1434) |            |                         |
|--|---------------------------|------------|-------------------------|---------------------------|------------|-------------------------|
|  | No. (%)                   |            | Standardized difference | No. (%)                   |            | Standardized difference |
|  | Nonexposed                | Exposed    |                         | Nonexposed                | Exposed    |                         |
| Volume of NICU in which infant was hospitalized at day 7, No. of infants |                           |            |                         |                           |            |                         |
| <20  | 183 (21.5)                | 113 (12.0) | 25.50                   | 124 (17.3)                | 108 (15.1) | 6.06                    |
| 21-30  | 150 (17.6)                | 227 (24.2) | 16.21                   | 137 (19.1)                | 145 (20.2) | 2.79                    |
| 31-40  | 132 (15.5)                | 111 (11.8) | 10.73                   | 102 (14.2)                | 104 (14.5) | 0.77                    |
| >40  | 386 (45.4)                | 487 (51.9) | 13.15                   | 354 (49.4)                | 360 (50.2) | 1.68                    |

Abbreviations: FGR, fetal growth restriction; NA, not applicable; NICU, neonatal intensive care unit.

<sup>a</sup> Birth weight z score based on Olsen curves.<sup>23</sup>

age, 27.3 [1.5] weeks in both groups) (eTable 1 in Supplement 1). An FSIQ score greater than -1 SD (ie,  $\geq 93$  points) was observed more frequently in exposed vs nonexposed infants (243 infants [61.4%] vs 206 infants [54.4%], respectively; OR, 1.33; 95% CI, 1.00-1.78; absolute risk increase in events [ie, the likelihood of having an FSIQ score  $>-1$  SD at age 5 years] per 100 infants, 7.01 [95% CI, 0.06-13.87];  $P = .048$ ) (Table 2; Figure 2). The ORs for an FSIQ score greater than -1 SD were 0.99 (95% CI, 0.67-1.47) among 408 boys, 1.89 (95% CI, 1.23-2.88) among 367 girls, 1.54 (95% CI, 0.92-2.59) among 237 infants born at 24 to 26 weeks' gestation, and 1.27 (95% CI, 0.90-1.79) among 538 infants born at 27 to 29 weeks' gestation.

### Inverse Probability of Treatment Weighted Analysis

In the analysis accounting for NICU clustering, the OR for the association between the exposure and the primary outcome, adjusted for gestational age and weighted by the inverse of the propensity score, was 1.58 (95% CI, 1.21-2.06) among 978 infants in the overall cohort (Figure 2).

### Instrumental Variable Analysis

In the overall cohort, the instrumental variable (ie, NICU preference) was associated with an amino acid intake between 3.51 and 4.50 g/kg/d at day 7 (eg, 8.6% in quartile 1 vs 41.7% in quartile 4 among exposed infants;  $P < .001$ ) (eTable 2 in Supplement 1) but not with antenatal corticosteroid receipt (eg, 58.0% in quartile 1 vs 63.6% in quartile 4;  $P = .08$ ), inborn status (eg, 85.0% in quartile 1 vs 88.4% in quartile 4;  $P = .13$ ), or NICU patient volume (eg, 16.3% in quartile 1 vs 19.5% in quartile 4 for small units with  $<20$  enrolled infants;  $P = .20$ ), which are quality markers that are usually associated with outcomes (eTable 3 in Supplement 1). The instrumental variable was not associated with other practice strategies already assessed in the EPIPAGE-2 study (eg, difference between observed and expected percentage, -8.0% in quartile 1 vs -2.6% in quartile 4 [ $P = .42$ ] for skin contact during the first 7 days; 6.9% in quartile 1 vs 1.2% in quartile 4 [ $P = .37$ ] for sedation during the first 7 days) (eFigure 4 in Supplement 1).<sup>34</sup> Using this instrumental variable approach, the partial  $F$  statistic for the instrumental variable in the first-stage model was 139, and the adjusted OR for the association between the exposure and the primary outcome among 978 participants was 1.30 (95% CI, 1.16-1.46) after adjustment for gestational age, birth weight z score, sex, and maternal educational level.

### Complementary Analyses

In the matched cohort, among 775 participants, a significant correlation was found between amino acid intake per 1.00 g/kg/d at day 7 and FSIQ score at 5 years ( $\beta = 2.43$  per 1-point increase in FSIQ score; 95% CI, 0.27-4.59;  $P = .03$ ). All correlations between amino acid intake at day 7 and FSIQ score as a continuous variable are shown in Figure 2. Among all correlated nutritional intake levels, only amino-acid intake levels at days 3 and 7 were correlated with FSIQ score (Spearman  $r = 0.09$  and 0.11, respectively) (eFigure 3 in Supplement 1).



Table 2. Characteristics and Outcomes of Nonexposed vs Exposed Infants

| Characteristic or outcome                                      | Overall cohort (n = 1789) |              |                        |              |         | Matched cohort (n = 1434) |              |                        |              |         |
|--|---------------------------|--------------|------------------------|--------------|---------|---------------------------|--------------|------------------------|--------------|---------|
|  | Infants, No. (n = 851)    | Nonexposed   | Infants, No. (n = 938) | Exposed      | P value | Infants, No. (n = 717)    | Nonexposed   | Infants, No. (n = 717) | Exposed      | P value |
| <b>Nutritional intake, mean (SD)</b>                           |                           |              |                        |              |         |                           |              |                        |              |         |
| <b>Day 3</b>   |                           |              |                        |              |         |                           |              |                        |              |         |
| Total volume, mL/kg/d  | 841                       | 127.0 (26.0) | 928                    | 137.0 (26.0) |         | 710                       | 128.0 (26.0) | 712                    | 136 (26.0)   |         |
| Percentage of parenteral nutrition                             | 837                       | 89.0 (57.0)  | 924                    | 90 (12.0)    |         | 706                       | 88 (54.0)    | 708                    | 92 (38.0)    |         |
| Protein, g/kg/d <sup>a</sup>                                   | 830                       | 2.5 (0.8)    | 928                    | 3.2 (0.7)    | NA      | 704                       | 2.5 (0.8)    | 712                    | 3.2 (0.7)    | NA      |
| Carbohydrates, g/kg/d  | 836                       | 10.9 (3.0)   | 931                    | 11.3 (2.9)   |         | 706                       | 10.9 (3.0)   | 714                    | 11.2 (2.9)   |         |
| Lipids, g/kg/d   | 826                       | 1.6 (1.1)    | 922                    | 2.0 (1.1)    |         | 701                       | 1.7 (1.1)    | 705                    | 2.0 (1.1)    |         |
| <b>Day 7</b>   |                           |              |                        |              |         |                           |              |                        |              |         |
| Total volume, mL/kg/d  | 851                       | 151.0 (28.0) | 938                    | 164.0 (22.0) |         | 714                       | 152.0 (28.0) | 715                    | 165.0 (22.0) |         |
| Percentage of parenteral nutrition                             | 851                       | 78.0 (34.0)  | 938                    | 80.0 (20.0)  |         | 694                       | 76.0 (36.0)  | 705                    | 80.0 (20.0)  |         |
| Protein, g/kg/d <sup>a</sup>                                   | 851                       | 2.9 (0.6)    | 938                    | 4.0 (0.2)    | NA      | 717                       | 3.0 (0.5)    | 717                    | 4.0 (0.2)    | NA      |
| Carbohydrates, g/kg/d  | 849                       | 13.6 (3.7)   | 937                    | 15.0 (3.6)   |         | 716                       | 13.8 (3.6)   | 716                    | 14.9 (3.5)   |         |
| Lipids, g/kg/d   | 840                       | 3.0 (1.5)    | 937                    | 3.6 (1.6)    |         | 715                       | 3.1 (1.5)    | 716                    | 3.6 (1.7)    |         |
| Receiving maternal breast milk, No. (%)                        | 851                       | 144 (16.9)   | 938                    | 122 (13.0)   |         | 717                       | 126 (17.6)   | 717                    | 99 (13.8)    |         |
| <b>Day 28</b>  |                           |              |                        |              |         |                           |              |                        |              |         |
| Alive, No. (%)   | 851                       | 769 (90.4)   | 938                    | 887 (94.6)   |         | 717                       | 669 (93.3)   | 717                    | 671 (93.6)   |         |
| Total volume, mL/kg/d  | 723                       | 158 (50.0)   | 820                    | 159.0 (23.0) |         | 651                       | 155.0 (29.0) | 642                    | 159.0 (33.0) |         |
| Percentage of parenteral nutrition                             | 723                       | 30 (37.0)    | 820                    | 26.0 (35.0)  |         | 654                       | 26.1 (35.2)  | 652                    | 25.2 (33.5)  |         |
| Protein, g/kg/d <sup>a</sup>                                   | 624                       | 3.1 (0.7)    | 701                    | 3.2 (0.7)    | NA      | 539                       | 3.1 (0.7)    | 534                    | 3.2 (0.7)    | NA      |
| Carbohydrates, g/kg/d  | 633                       | 14.6 (3.4)   | 706                    | 13.9 (3.9)   |         | 546                       | 14.6 (3.3)   | 537                    | 14.3 (3.5)   |         |
| Lipids, g/kg/d   | 627                       | 5.0 (2.0)    | 701                    | 5.2 (1.9)    |         | 541                       | 5.1 (2.0)    | 533                    | 5.2 (1.8)    |         |
| Receiving maternal breast milk, No. (%)                        | 851                       | 154 (18.1)   | 938                    | 147 (15.7)   |         | 717                       | 134 (18.7)   | 717                    | 114 (15.9)   |         |
| <b>Outcome at 36 wk postmenstrual age</b>                      |                           |              |                        |              |         |                           |              |                        |              |         |
| Alive, No. (%)   | 851                       | 746 (87.7)   | 938                    | 871 (92.9)   |         | 717                       | 652 (90.9)   | 717                    | 657 (91.6)   |         |
| Alive without severe morbidity, No. (%) <sup>b</sup>           | 821                       | 528 (64.3)   | 881                    | 619 (70.3)   |         | 652                       | 432 (66.3)   | 635                    | 440 (69.3)   |         |
| Delta weight z score between discharge and birth, mean (SD)    | 692                       | -1.26 (0.75) | 791                    | -1.11 (0.74) | NA      | 603                       | -1.25 (0.74) | 590                    | -1.12 (0.72) | NA      |
| Duration of any assisted ventilation up to 36 wk, mean (SD), d | 843                       | 32.4 (23.5)  | 932                    | 30.2 (23.7)  |         | 644                       | 33.8 (24.0)  | 655                    | 31.7 (24.0)  |         |
| Duration of parenteral nutrition up to 36 wk, mean (SD), d     | 668                       | 27.3 (15.3)  | 784                    | 26.0 (12.0)  |         | 585                       | 26.6 (15.1)  | 589                    | 26.1 (12.2)  |         |
| <b>Type of nutrition at discharge, No. (%)</b>                 |                           |              |                        |              |         |                           |              |                        |              |         |
| Alive at discharge   | 851                       | 741 (87.1)   | 938                    | 864 (92.1)   |         | 717                       | 649 (90.5)   | 717                    | 651 (90.8)   |         |
| Maternal breast milk   | 741                       | 237 (32.0)   | 864                    | 307 (35.5)   |         | 649                       | 212 (32.7)   | 651                    | 221 (33.9)   |         |
| Nutrient-enriched maternal breast milk                         | 741                       | 112 (15.1)   | 864                    | 114 (13.2)   |         | 649                       | 102 (15.7)   | 651                    | 83 (12.7)    |         |
| Donated breast milk  | 741                       | 23 (3.1)     | 864                    | 21 (2.4)     | NA      | 649                       | 16 (2.5)     | 651                    | 13 (2.0)     | NA      |
| Nutrient-enriched formula                                      | 741                       | 183 (24.7)   | 864                    | 219 (25.3)   |         | 649                       | 165 (25.4)   | 651                    | 176 (27.0)   |         |
| Standard formula   | 741                       | 18 (2.4)     | 864                    | 16 (1.9)     |         | 649                       | 15 (2.3)     | 651                    | 10 (1.5)     |         |
| Specific formula   | 741                       | 94 (12.7)    | 864                    | 86 (10.0)    |         | 649                       | 76 (11.7)    | 651                    | 66 (10.1)    |         |
| Missing data   | 741                       | 74 (10.0)    | 864                    | 74 (8.6)     |         | 649                       | 63 (9.7)     | 651                    | 82 (12.6)    |         |
| <b>Cognitive outcomes at age 5 y</b>                           |                           |              |                        |              |         |                           |              |                        |              |         |
| Alive at age 5 y, No. (%)                                      | 851                       | 735 (86.4)   | 938                    | 858 (91.5)   | .001    | 717                       | 644 (89.8)   | 717                    | 646 (90.1)   | .86     |
| <b>FSIQ</b>  |                           |              |                        |              |         |                           |              |                        |              |         |
| Data available, No. (%)  | 735                       | 432 (58.8)   | 858                    | 546 (63.6)   | .047    | 644                       | 379 (58.9)   | 646                    | 396 (61.3)   | .37     |
| Score, mean (SD)   | 432                       | 92.3 (15.7)  | 546                    | 95.7 (15.6)  | .001    | 379                       | 93.6 (15.2)  | 396                    | 95.7 (15.5)  | .03     |
| Score ≥93, No. (%) <sup>c</sup>                                | 432                       | 205 (47.5)   | 546                    | 208 (38.1)   | .003    | 379                       | 206 (54.4)   | 396                    | 243 (61.4)   | .048    |

(continued)

Table 2. Characteristics and Outcomes of Nonexposed vs Exposed Infants (continued)

| Characteristic or outcome   | Overall cohort (n = 1789) |             |                        |             | Matched cohort (n = 1434) |                        |             |                        |             |         |
|-----------------------------|---------------------------|-------------|------------------------|-------------|---------------------------|------------------------|-------------|------------------------|-------------|---------|
|                             | Infants, No. (n = 851)    | Nonexposed  | Infants, No. (n = 938) | Exposed     | P value                   | Infants, No. (n = 717) | Nonexposed  | Infants, No. (n = 717) | Exposed     | P value |
| WPPSI-IV score, mean (SD)   |                           |             |                        |             |                           |                        |             |                        |             |         |
| Verbal comprehension        | 436                       | 96.0 (17.1) | 550                    | 98.4 (17.1) | .03                       | 383                    | 97.0 (16.9) | 399                    | 98.8 (16.6) | .30     |
| Visual-perceptual reasoning | 439                       | 93.6 (15.5) | 551                    | 95.9 (14.7) | .02                       | 385                    | 94.5 (15.0) | 401                    | 96.1 (14.4) | .13     |
| Fluid reasoning             | 435                       | 94.6 (15.8) | 551                    | 97.1 (14.8) | .01                       | 384                    | 95.1 (15.4) | 402                    | 97.3 (14.6) | .04     |
| Working memory              | 437                       | 93.0 (15.2) | 548                    | 95.1 (13.7) | .02                       | 385                    | 93.6 (13.7) | 400                    | 95.2 (14.0) | .09     |
| Processing speed            | 433                       | 93.7 (15.2) | 548                    | 95.2 (15.4) | .12                       | 381                    | 94.3 (14.9) | 399                    | 95.0 (15.6) | .52     |

Abbreviations: FSIQ, full-scale IQ; NA, not applicable; WPPSI-IV, Wechsler Preschool and Primary Scale of Intelligence, 4th edition.


<sup>a</sup> Sum of enteral protein and intravenous amino acid supply.

<sup>b</sup> Severe morbidity was defined by the presence of one of the following events: intraventricular hemorrhage with ventricular dilatation (grade 3), intraparenchymal hemorrhage (defined as large unilateral parenchymal hyperdensity or large unilateral porencephalic cyst), cystic periventricular leukomalacia (defined as periventricular

white matter echolucencies during ultrasonography), severe bronchodysplasia treatment with oxygen for at least 28 days with need for oxygen at 30% or higher, receipt of mechanical ventilation, continuous positive airway pressure at 36 weeks' postmenstrual age, necrotizing enterocolitis (Bell stage 2 or 3), or retinopathy at stage 3 or higher.

<sup>c</sup> Equivalent to z score of -1 SD.

Figure 2. Multivariable Analysis of the Association Between Amino Acid Intake at 7 Days After Birth and FSIQ at Age 5 Years



Among infants with complete data available. Model 1 was adjusted for gestational age, sex, birth weight z score, and maternal educational level. Model 2 was adjusted for gestational age and weighted by the inverse of the propensity score. Model 3 was adjusted for gestational age and weighted by the inverse of the propensity score, accounting for neonatal intensive care unit clustering. A, The position of each square represents the point estimate of the exposure effect. Horizontal lines represent 95% CIs. Results are expressed as number of events per number of participants. B, The position of each square represents the point estimate of the β coefficient between amino acid intake at 7 days after birth as a continuous variable and FSIQ at age 5 years. FSIQ indicates full-scale IQ; OR, odds ratio.

Magnetic resonance imaging data were available for 170 infants in the overall cohort and 134 infants in the matched cohort. The gestational ages and birth weight z scores were not significantly different between the subgroup of infants with MRI data vs the entire cohort (mean [SD] gestational age, 27.36 [1.33] weeks vs 27.15 [1.35] weeks, respectively;  $P = .14$ ; mean [SD] z score, -0.09 [1.00] vs -0.08 [0.96];  $P = .82$ ). In both the overall and matched cohorts, amino acid intake at day 7 was correlated with white matter area (overall cohort:  $n = 170$ ;  $\beta = 170$  [95% CI, 30-310;  $P = .02$ ]; matched cohort:  $n = 134$ ;  $\beta = 144$  per  $\text{mm}^2$  [95% CI, 3-285 per  $\text{mm}^2$ ;  $P = .045$ ]), anisotropy of the corpus callosum (overall cohort:  $n = 62$ ;  $\beta = 0.018$  [95% CI, 0.015-0.021;  $P < .001$ ]; matched cohort:  $n = 50$ ;  $\beta = 0.018$  [95% CI, 0.016-0.021;  $P < .001$ ]), left superior longitudinal fasciculus (overall cohort:  $n = 51$ ;  $\beta = 0.017$  [95% CI, 0.010-0.025;  $P < .001$ ]; matched cohort:  $n = 42$ ;  $\beta = 0.018$  [95% CI, 0.010-0.025;  $P < .001$ ]), and right superior longitudinal fasciculus (overall cohort:  $n = 51$ ;  $\beta = 0.012$  [95% CI, 0.005-0.019;  $P = .002$ ]; matched cohort:  $n = 42$ ;  $\beta = 0.014$  [95% CI, 0.005-0.024;  $P = .003$ ]) measured by MRI at term (eTable 4 and eTable 5 in Supplement 1).

The association between amino acid intake at day 7 (split into 4 subgroups: <3.00, 3.01-3.50, 3.51-4.00, and 4.01-4.50 g/kg/d), FSIQ score, and MRI data are shown in **Figure 3**. In the matched cohort, the white matter area was significantly smaller among 56 infants with amino acid intake of 3.51 to 4.00 g/kg/d (mean [SD] area, 2380 [500] mm<sup>2</sup>) compared with 78 infants with amino acid intake of 4.01 to 4.50 g/kg/d (mean [SD] area, 2580 [510] mm<sup>2</sup>;  $P = .02$ ) after adjusting for gestational age, birth weight z score, and sex and weighting by the inverse of the propensity score. The mean fractional anisotropy of the corpus callosum was significantly smaller among 13 infants with amino acid intake of less than 3.00 g/kg/d (mean [SD], 0.17 [0.02]) compared with 11 infants with intake of 4.01 to 4.50 g/kg/d (mean [SD], 0.21 [0.03];  $P < .001$ ) after adjustment.

Amino acid intake at 7 days after birth was significantly correlated with carbohydrate intake (Spearman  $r = 0.10$ ;  $P < .001$ ) and lipid intake (Spearman  $r = 0.12$ ;  $P < .001$ ), but neither carbohydrate intake (Spearman  $r = 0.03$ ;  $P = .46$ ) nor lipid intake (Spearman  $r = 0.02$ ;  $P = .66$ ) was correlated with FSIQ score (eTable 6 and eFigure 4 in [Supplement 1](#)). In the overall cohort, the negative control analysis of propensity score did not reveal any association between early amino acid intake greater than 3.50 g/kg/d and survival without morbidity at 36 weeks' postmenstrual age (OR, 1.01; 95% CI, 0.76-1.35) after adjustment for propensity score.

### Sensitivity Analyses

When multiple imputations were used in the matched cohort, the adjusted OR for the association between the exposure and the primary outcome was 1.35 (95% CI, 1.05-1.75). In the overall cohort, the observed correlation between amino acid intake and FSIQ score using multiple imputation based on propensity score matching or weighting by the inverse of propensity score was consistent with the analysis among participants with complete data (eFigure 5 in [Supplement 1](#)). The correlations between amino acid intake and FSIQ score among subgroups of the matched cohort, corresponding to potential confounding factors, are shown in eTable 7 in [Supplement 1](#). Among 226 of 465 infants with severe illness during the first week of life, the  $\beta$  correlation was 4.05 (95% CI, 0.98-7.12;  $P = .01$ ), and higher amino acid intake at day 7 was not associated with an increased risk of death (OR, 1.03; 95% CI, 0.62-1.73;  $P = .90$ ).


### Discussion

In the EPIPAGE-2 nationwide population-based cohort study, amino acid intake higher than 3.50 g/kg/d at 7 days after birth, used as a proxy for early amino acid intake, was independently associated with an increase in the likelihood of surviving with an FSIQ score greater than -1 SD at age 5 years. Moreover, we observed a correlation between amino acid intake at 7 days after birth as a continuous variable and FSIQ score. Among a subgroup of infants enrolled in the EPIRMEX study, a correlation was found between amino acid intake and white matter area or anisotropy of several white matter tracts identified by an MRI scan performed at term.

These findings are inconsistent with several randomized studies that did not find any significant benefit during follow-up among children exposed to high early amino acid intake. However, the statistical power of those studies was relatively weak, and the follow-up extended to only 18 or 24 months of corrected age, which were clear limitations. The significant positive association between FSIQ score and amino acid intake observed among girls in the current study was consistent with results from an earlier observational study comparing 2 consecutive cohorts in which preterm female infants with higher amino acid intake had an increased likelihood of reaching a Bayley mental developmental index of 85 points or higher at age 2 years.<sup>35</sup> This association, which was observed mainly in girls, is probably explained by differences in metabolism and body composition between girls and boys, suggesting the need to perform prespecified sex-specific analyses in future randomized clinical trials.<sup>36</sup>

The association between early nutrition and MRI results has been reported in few studies of preterm infants.<sup>10,11,37-40</sup> The designs, findings from MRI, and characteristics of nutritional support

Figure 3. Association Between Amino Acid (AA) Intake at 7 Days After Birth, Full-Scale IQ (FSIQ) at Age 5 Years, and Magnetic Resonance Imaging (MRI) Results at Equivalent Term, Categorized by 4 Subgroups of AA Intake



Adjusted for gestational age, biological sex, and birth weight z score weighted by the inverse of the propensity score and accounting for neonatal intensive care unit clustering. The dotted red line (graphs on top left) represents -1 SD of FSIQ among full-term infants enrolled in the EPIPAGE-2 follow-up study.<sup>1</sup> Fractional anisotropy (graphs on right) is a scalar value between 0 and 1 that describes the extent of anisotropy in the diffusion process. A value of 0 indicates that diffusion is isotropic and unrestricted in all directions. A value of 1 indicates that diffusion is occurring only along 1 axis and is fully

restricted in all other directions. The reference population is the population of full-term infants enrolled in the EPIPAGE-2 follow-up study.<sup>1</sup> This reference population was not hospitalized during the neonatal period; therefore, the protein intake on day 7 was unknown and very low because protein was provided solely from milk. The equivalent term is the conventional formulation used to indicate the MRI was performed at approximately 40 weeks' postmenstrual age (ie, corrected age).

varied between these studies and likely accounted for their inconsistent conclusions. Some studies<sup>9-11,38</sup> found an association between nutrition, brain growth, and accelerated white matter maturation, whereas others<sup>37,39</sup> did not. In our study, early amino acid intake was associated with increases in white matter area and increased anisotropy of several white matter tracts assessed by MRI at term. In a recent study by the Protein, Insulin, and Neonatal Outcomes (PIANO) group,<sup>11</sup> in which MRI scans were obtained at age 7 years, the investigators noted that greater neonatal amino acid intake was positively associated with connectivity strength. These studies<sup>9-11,38</sup> suggest that optimizing early protein intake in preterm neonates may represent a potential avenue to improve brain maturation in very preterm infants. These findings<sup>10,11,38</sup> are consistent with an experimental study in rodents,<sup>41</sup> which reported that protein deficiency during brain development had negative consequences for white matter development and maturation.

### Strengths and Limitations

This study has several strengths. These strengths include the population-based cohort design and the prospective enrollment of all infants born preterm in France in 2011. Furthermore, the data on nutrition were prospectively collected using a detailed standardized questionnaire. Therefore, comprehensive and accurate information on nutritional strategies was available. We observed a significant correlation between amino acid, carbohydrate, and lipid intake at day 7, but only amino acid intake was correlated with FSIQ score at age 5 years. The difference in nutritional strategies observed during the first week of life was no longer observed at day 28 or at discharge, emphasizing the importance of early nutrition in the association with long-term outcomes. Moreover, we did not observe any increase in mortality among exposed preterm infants with initial severe illness, contrary to what was observed among critically ill term infants exposed to early amino acid intake.<sup>42</sup>

This study also has limitations. The main limitation is potential uncontrolled confounding. We used multiple statistical approaches to reduce bias as much as possible. To control for the indication bias inherent in this type of study, we performed a propensity score analysis and rigorously adjusted for confounding factors, minimizing the likelihood of incorrectly attributing the association to early amino acid intake. The results of the instrumental variable analysis confirmed those of the main analysis. Moreover, we did not observe any association between the characteristics of the NICUs and the nutritional strategies used in those NICUs, suggesting a lack of performance bias. The reason a specific nutrition strategy was chosen in a given NICU may have been associated with the medical staff's interest in nutritional care or the extent of the staff's agreement with international guidelines. These factors probably explain the wide range of nutritional practices observed in this national cohort, confirming the broad variation in practices observed across Europe.<sup>19</sup>

The second limitation is that the primary outcome was known for only 60% of children in the present study; however, the sensitivity analyses based on the imputed data confirmed the findings of the main analysis. The third limitation is the small number of children with MRI data available, which precludes the performance of correlation mediation analyses to ascertain whether the impact for FSIQ was mediated by the effect on white matter volume or maturation.

---

### Conclusions

In this nationwide population-based cohort study of preterm infants born at less than 30 weeks' gestation, high early amino acid intake was independently associated with a greater likelihood of surviving with an FSIQ score greater than -1 SD at age 5 years. Well-designed randomized studies with long-term follow-up and prespecified sex-specific analyses are needed to confirm these results.

## ARTICLE INFORMATION

**Accepted for Publication:** September 22, 2021.

**Published:** November 30, 2021. doi:10.1001/jamanetworkopen.2021.35452

**Open Access:** This is an open access article distributed under the terms of the [CC-BY License](#). © 2021 Rozé JC et al. *JAMA Network Open*.

**Corresponding Author:** Jean-Christophe Rozé, MD, PhD, Department of Neonatal Medicine, Nantes University Hospital, 36 Blvd Jean Monnet, Nantes 44000, France ([jean-christophe.roze@inserm.fr](mailto:jean-christophe.roze@inserm.fr)).

**Author Affiliations:** Department of Neonatal Medicine, Nantes University Hospital, Nantes, France (Rozé, Flamant); Epidémiologie Clinique, Centre d'Investigation Clinique, Nantes University Hospital, Institut National de la Santé et de la Recherche Médicale (INSERM), Nantes, France (Rozé, Flamant); Unité Mixte de Recherche (UMR) 1280, Physiologie des Adaptations Nutritionnelles, Nantes University, Institut National de la Recherche Agronomique (INRAE), Nantes, France (Rozé, Darmaun, Moyon); UMR 1253, iBrain, Tours University, INSERM, Tours, France (Morel, Favrais, Saliba); Department of Neonatal Medicine, Assistance Publique Hôpitaux de Paris, Necker Enfants Malades Hospital, Paris, France (Lapillonne); Department of Neonatal Medicine, Rouen University Hospital, Rouen, France (Marret); Department of Neonatal Medicine, Assistance Publique Hôpitaux de Paris, Trousseau Hospital, Paris, France (Guellec); EA 3804, Department of Neonatal Medicine, Reims University Hospital, Champagne-Ardennes University, Reims, France (Bednarek, Loron); Obstetrical Perinatal and Pediatric Epidemiology Research Team, U1153 Epidemiology and Biostatistics Sorbonne, University of Paris, INSERM, Paris, France (Marchand-Martin, Benhammou, Pierrat, Ancel); Department of Neonatal Medicine, Jeanne de Flandre Hospital, Lille University Hospital, Lille, France (Pierrat, Storme); Department of Neonatal Medicine, Angers University Hospital, Angers, France (Gascoin); Department of Neonatal Medicine, Tours University Hospital, Tours, France (Mitanchez); Department of Neonatal Medicine, Montpellier University Hospital, Montpellier, France (Cambonie, Gire); Department of Neonatology, Assistance Publique Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France (Tosello); Department of Neonatology, University of Paris, Robert-Debre Hospital, Assistance Publique Hôpitaux de Paris, Paris, France (Biran); Department of Neonatology, Hospices Civils de Lyon, Lyon, France (Claris, Picaud); Department of Neonatology, Rennes University Hospital, Rennes, France (Beuchée); Department of Neonatology, Centre Inter-Communal de Créteil, Créteil, France (Durrmeyer); NeuroDiderot, Robert-Debré Hospital, University of Paris, INSERM, Paris, France (Gressens); Clinical Investigation Centre P1419, Assistance Publique-Hôpitaux de Paris, Paris, France (Ancel).

**Author Contributions:** Drs Rozé and Ancel had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**Concept and design:** Rozé, Morel, Lapillonne, Marret, Bednarek, Saliba, Ancel.

**Acquisition, analysis, or interpretation of data:** Rozé, Morel, Lapillonne, Marret, Guellec, Darmaun, Bednarek, Moyon, Marchand-Martin, Benhammou, Pierrat, Flamant, Gascoin, Cambonie, Tosello, Biran, Claris, Picaud, Favrais, Beuchée, Loron, Gire, Durrmeyer, Gressens, Ancel.

**Drafting of the manuscript:** Rozé, Saliba.

**Critical revision of the manuscript for important intellectual content:** Rozé, Morel, Lapillonne, Marret, Guellec, Darmaun, Bednarek, Moyon, Marchand-Martin, Benhammou, Pierrat, Flamant, Gascoin, Mitanchez, Cambonie, Storme, Tosello, Biran, Claris, Picaud, Favrais, Beuchée, Loron, Gire, Durrmeyer, Gressens, Ancel.

**Statistical analysis:** Rozé, Moyon, Marchand-Martin, Ancel.

**Obtained funding:** Saliba, Ancel.

**Administrative, technical, or material support:** Morel, Benhammou, Flamant, Biran, Claris, Loron, Saliba.

**Supervision:** Benhammou, Saliba, Ancel.

**Conflict of Interest Disclosures:** None reported.

**Funding/Support:** The EPIPAGE 2 study was supported by grant ANR-11-EQPX-0038 from the National Research Agency (via the French Equipex Program of Investments in the Future); funding from the French Institute of Public Health Research/Institute of Public Health and its partners at the French Health Ministry, the National Institute of Cancer, the National Institute of Health and Medical Research, and the National Solidarity Fund for Autonomy; and funding from the PremUp Foundation. The EPIRMEX study was supported by grant PHRN11-2011-AO0740-41 from the French Health Ministry and the National Institute of Health and Medical Research.

**Role of the Funder/Sponsor:** The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Group Information:** Members of the Nutrition EPIPAGE-2 Study Group and the EPIRMEX Study Group are listed in [Supplement 2](#).

## REFERENCES

1. Pierrat V, Marchand-Martin L, Marret S, et al; EPIPAGE-2 Writing Group. Neurodevelopmental outcomes at age 5 among children born preterm: EPIPAGE-2 cohort study. *BMJ*. 2021;373:n741. doi:10.1136/bmj.n741
2. Ziegler EE, Thureen PJ, Carlson SJ. Aggressive nutrition of the very low birthweight infant. *Clin Perinatol*. 2002;29(2):225-244. doi:10.1016/S0095-5108(02)00007-6
3. Hay WW Jr, Lucas A, Heird WC, et al. Workshop summary: nutrition of the extremely low birth weight infant. *Pediatrics*. 1999;104(6):1360-1368. doi:10.1542/peds.104.6.1360
4. Denne SC. Protein and energy requirements in preterm infants. *Semin Neonatol*. 2001;6(5):377-382. doi:10.1053/siny.2001.0059
5. Koletzko B, Goulet O, Hunt J, Krohn K, Shamir R; Parenteral Nutrition Guidelines Working Group; European Society for Clinical Nutrition and Metabolism; European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN); European Society of Paediatric Research (ESPR). 1. Guidelines on paediatric parenteral nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), supported by the European Society of Paediatric Research (ESPR). *J Pediatr Gastroenterol Nutr*. 2005;41(suppl 2):S1-S87. doi:10.1097/O1.mpg.0000181841.07090.f4
6. van den Akker CHP, Schierbeek H, Minderman G, et al. Amino acid metabolism in the human fetus at term: leucine, valine, and methionine kinetics. *Pediatr Res*. 2011;70(6):566-571. doi:10.1203/PDR.0b013e31823214d1
7. van Goudoever JB, Carnielli V, Darmaun D, Sainz de Pipaon M; ESPGHAN/ESPEN/ESPR/CSPEN Working Group on Pediatric Parenteral Nutrition. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: amino acids. *Clin Nutr*. 2018;37(6 Pt B):2315-2323. doi:10.1016/j.clnu.2018.06.945
8. Stephens BE, Walden RV, Gargus RA, et al. First-week protein and energy intakes are associated with 18-month developmental outcomes in extremely low birth weight infants. *Pediatrics*. 2009;123(5):1337-1343. doi:10.1542/peds.2008-0211
9. Schneider J, Fischer Fumeaux CJ, Duerden EG, et al. Nutrient intake in the first two weeks of life and brain growth in preterm neonates. *Pediatrics*. 2018;141(3):e20172169. doi:10.1542/peds.2017-2169
10. Coviello C, Keunen K, Kersbergen KJ, et al. Effects of early nutrition and growth on brain volumes, white matter microstructure, and neurodevelopmental outcome in preterm newborns. *Pediatr Res*. 2018;83(1-1):102-110. doi:10.1038/pr.2017.227
11. Duerden EG, Thompson B, Poppe T, et al; PIANO Study Group. Early protein intake predicts functional connectivity and neurocognition in preterm born children. *Sci Rep*. 2021;11(1):4085. doi:10.1038/s41598-021-83125-z
12. Osborn DA, Schindler T, Jones LJ, Sinn JK, Bolisetty S. Higher versus lower amino acid intake in parenteral nutrition for newborn infants. *Cochrane Database Syst Rev*. 2018;3(3):CD005949. doi:10.1002/14651858.CD005949.pub2
13. Burattini I, Bellagamba MP, Spagnoli C, et al; Marche Neonatal Network. Targeting 2.5 versus 4 g/kg/day of amino acids for extremely low birth weight infants: a randomized clinical trial. *J Pediatr*. 2013;163(5):1278-1282. doi:10.1016/j.jpeds.2013.06.075
14. Roelants JA, Vlaardingerbroek H, van den Akker CHP, de Jonge RCJ, van Goudoever JB, Vermeulen MJ. Two-year follow-up of a randomized controlled nutrition intervention trial in very low-birth-weight infants. *JPEN J Parenter Enteral Nutr*. 2018;42(1):122-131. doi:10.1177/0148607116678196
15. Balakrishnan M, Jennings A, Przystac L, et al. Growth and neurodevelopmental outcomes of early, high-dose parenteral amino acid intake in very low birth weight infants: a randomized controlled trial. *JPEN J Parenter Enteral Nutr*. 2018;42(3):597-606. doi:10.1177/0148607117696330
16. Uthaya S, Liu X, Babalis D, et al. Nutritional evaluation and optimisation in neonates: a randomized, double-blind controlled trial of amino acid regimen and intravenous lipid composition in preterm parenteral nutrition. *Am J Clin Nutr*. 2016;103(6):1443-1452. doi:10.3945/ajcn.115.125138
17. van den Akker CHP, te Braake FWJ, Weisglas-Kuperus N, van Goudoever JB. Observational outcome results following a randomized controlled trial of early amino acid administration in preterm infants. *J Pediatr Gastroenterol Nutr*. 2014;59(6):714-719. doi:10.1097/MPG.0000000000000549
18. Concato J, Horwitz RJ. Beyond randomised versus observational studies. *Lancet*. 2004;363(9422):1660-1661. doi:10.1016/S0140-6736(04)16285-5
19. Lapillonne A, Carnielli VP, Embleton ND, Mihatsch W. Quality of newborn care: adherence to guidelines for parenteral nutrition in preterm infants in four European countries. *BMJ Open*. 2013;3(9):e003478. doi:10.1136/bmjopen-2013-003478

20. Watkins MW, Beaujean AA. Bifactor structure of the Wechsler Preschool and Primary Scale of Intelligence—fourth edition. *Sch Psychol Q*. 2014;29(1):52-63. doi:10.1037/spq0000038
21. Morel B, Bertault P, Favrais G, et al; EPIRMEX Study Group. Automated brain MRI metrics in the EPIRMEX cohort of preterm newborns: correlation with the neurodevelopmental outcome at 2 years. *Diagn Interv Imaging*. 2021;102(4):225-232. doi:10.1016/j.diii.2020.10.009
22. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. *Biometrika*. 1983;70(1):41-55. doi:10.1093/biomet/70.1.41
23. Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS. New intrauterine growth curves based on United States data. *Pediatrics*. 2010;125(2):e214-e224. doi:10.1542/peds.2009-0913
24. Austin PC. A comparison of 12 algorithms for matching on the propensity score. *Stat Med*. 2014;33(6):1057-1069. doi:10.1002/sim.6004
25. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. *Biometrika*. 1986;73(1):13-22. doi:10.1093/biomet/73.1.13
26. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. *Stat Med*. 2004;23(19):2937-2960. doi:10.1002/sim.1903
27. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. *JAMA*. 2007;297(3):278-285. doi:10.1001/jama.297.3.278
28. Greenland S. An introduction to instrumental variables for epidemiologists. *Int J Epidemiol*. 2000;29(4):722-729. doi:10.1093/ije/29.4.722
29. Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. *J Health Econ*. 2008;27(3):531-543. doi:10.1016/j.jhealeco.2007.09.009
30. Bound J, Jaeger DA, Baker RM. Problems with instrumental variable estimation when the correlation between the instruments and the endogenous explanatory variable is weak. *J Am Stat Assoc*. 1995;90(430):443-450. doi:10.1080/01621459.1995.10476536
31. Pierrat V, Marchand-Martin L, Arnaud C, et al; EPIPAGE-2 Writing Group. Neurodevelopmental outcome at 2 years for preterm children born at 22 to 34 weeks' gestation in France in 2011: EPIPAGE-2 cohort study. *BMJ*. 2017;358:j3448. doi:10.1136/bmj.j3448
32. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. *Stat Med*. 1991;10(4):585-598. doi:10.1002/sim.4780100410
33. Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. *Epidemiology*. 2010;21(3):383-388. doi:10.1097/EDE.0b013e3181d61eeb
34. Rozé JC, Ancel PY, Marchand-Martin L, et al; EPIFLORE Study Group. Assessment of neonatal intensive care unit practices and preterm newborn gut microbiota and 2-year neurodevelopmental outcomes. *JAMA Netw Open*. 2020;3(9):e2018119. doi:10.1001/jamanetworkopen.2020.18119
35. Christmann V, Roeleveld N, Visser R, et al. The early postnatal nutritional intake of preterm infants affected neurodevelopmental outcomes differently in boys and girls at 24 months. *Acta Paediatr*. 2017;106(2):242-249. doi:10.1111/apa.13669
36. Tottman AC, Oliver CJ, Alsweiler JM, Cormack BE. Do preterm girls need different nutrition to preterm boys? sex-specific nutrition for the preterm infant. *Pediatr Res*. 2021;89(2):313-317. doi:10.1038/s41390-020-01252-1
37. Vasu V, Durighel G, Thomas EL, et al. Preterm nutritional intake and MRI phenotype at term age: a prospective observational study. *BMJ Open*. 2014;4(5):e005390. doi:10.1136/bmjopen-2014-005390
38. Strommen K, Blakstad EW, Moltu SJ, et al. Enhanced nutrient supply to very low birth weight infants is associated with improved white matter maturation and head growth. *Neonatology*. 2015;107(1):68-75. doi:10.1159/000368181
39. Power VA, Spittle AJ, Lee KJ, et al. Nutrition, growth, brain volume, and neurodevelopment in very preterm children. *J Pediatr*. 2019;215:50-55. doi:10.1016/j.jpeds.2019.08.031
40. van Beek PE, Claessens NHP, Makropoulos A, et al. Increase in brain volumes after implementation of a nutrition regimen in infants born extremely preterm. *J Pediatr*. 2020;223:57-63. doi:10.1016/j.jpeds.2020.04.063
41. Rideau Batista Novais A, Pham H, Van de Looij Y, et al. Transcriptomic regulations in oligodendroglial and microglial cells related to brain damage following fetal growth restriction. *Glia*. 2016;64(12):2306-2320. doi:10.1002/glia.23079



42. van Puffelen E, Vanhorebeek I, Joosten KFM, Wouters PJ, Van den Berghe G, Verbruggen SCAT. Early versus late parenteral nutrition in critically ill, term neonates: a preplanned secondary subgroup analysis of the PEPANIC multicentre, randomised controlled trial. *Lancet Child Adolesc Health*. 2018;2(7):505-515. doi:10.1016/S2352-4642(18)30131-7

#### SUPPLEMENT 1.

**eMethods 1.** Magnetic Resonance Imaging Examination and Interpretation

**eMethods 2.** Instrumental Variable Approach

**eTable 1.** Characteristics of Preterm Infants Alive at Age 5 Years 6 Months With and Without FSIQ Score

**eTable 2.** Association Between Instrumental Variable and Protein Intake of More Than 3.50 g/kg per Day at Day 7 After Birth in the Overall Cohort

**eTable 3.** Instrumental Variable and Covariates in the Overall Cohort

**eTable 4.** Correlation Between Protein Intake at Day 7 After Birth (as a Continuous Variable) and Data From Magnetic Resonance Imaging at Term in the Matched Cohort

**eTable 5.** Correlation Between Protein Intake at Day 7 After Birth (as a Continuous Variable) and Data From Magnetic Resonance Imaging at Term in Overall Cohort

**eTable 6.** Nonadjusted Correlation Between FSIQ Assessed at Age 5 Years and Nutritional Data Collected at Days 3 and 7 After Birth in the Overall and Matching Cohorts

**eTable 7.** Correlation Between Protein Intake at Day 7 After Birth (as a Continuous Variable) and FSIQ at Age 5 Years in Matching Cohort by Subgroup

**eFigure 1.** Association Between NICU Patient Volume and Protein Intake of More than 3.50 g/kg per Day at Day 7 After Birth

**eFigure 2.** Propensity Score Distribution in Nonexposed vs Exposed Groups and Receiver Operating Characteristic Curve of the Model

**eFigure 3.** Nonadjusted Correlation Between Macronutrient Intake at Days 3, 7, and 28 After Birth and FSIQ in the Matched Cohort

**eFigure 4.** Strategies of NICUs According to Quartile of Instrumental Variable, Corresponding to the NICU's Preference for Protein Intake Greater Than 3.50 g/kg per Day

**eFigure 5.** Multivariable Analysis of Survival With FSIQ More Than  $-1$  SD (FSIQ Score  $\geq 93$ ) Among Preterm Infants With Protein Intake Known at Day 7 After Birth, in All Cases Using Multiple Imputations

**eReferences**

#### SUPPLEMENT 2.

**Nonauthor Collaborators.** Members of Nutrition EPIPAGE-2 Study Group and EPIRMEX Study Group